Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

This is an Open Access article that has been identified as being free of known restrictions under copyright law, including all related and neighboring rights (https://creativecommons.org/publicdomain/mark/1.0/). You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission.

PMC Copyright notice

Figure 3. — Effects of N-809 on NK cell phenotypic markers. Healthy donor NK cells were incubated ±N-809 (37.5 ng/ml) for 24h before being stained for multicolor flow cytometry. (a) Table of markers with increased or decreased expression after N-809 treatment. (b) Representative histograms of four phenotypic NK markers showing the change in expression between untreated cells (blue outline) and N-809‒treated cells (red shaded). Perforin expression was >90% for 3/4 donors, with a slight increase in percent expression and MFI after N-809 treatment, whereas the donor with the lowest expression levels (78.9%) had a greater increase in perforin with treatment. Markers that were stained for, but did not consistently change with treatment: CD11a, CD11c, CD158a, CD56, CD27, FasL, TRAIL, PD-L1, and 2B4. Similar results were seen for three additional donors (Supplemental Table S3).